

Zdeněk Trávníček<sup>a\*</sup> and Igor Popa<sup>b</sup><sup>a</sup>Department of Inorganic Chemistry, Faculty of Science, Palacký University, Křížkovského 10, CZ-771 47 Olomouc, Czech Republic, and<sup>b</sup>Laboratory of Growth Regulators, Palacký University, and Institute of Experimental Botany, AS CR, Palacký University, Šlechtitelů 11, CZ-783 71 Olomouc, Czech RepublicCorrespondence e-mail:  
zdenek.travnicek@upol.cz

## Key indicators


Single-crystal X-ray study  
 $T = 105\text{ K}$   
Mean  $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$   
 $R$  factor = 0.041  
 $wR$  factor = 0.091  
Data-to-parameter ratio = 12.7For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

## 2-Chloro-6-[(4-hydroxy-3,5-dimethoxybenzyl)amino]-9-isopropylpurine

The structure of the title compound,  $\text{C}_{17}\text{H}_{20}\text{ClN}_5\text{O}_3$ , consists of discrete molecules of a 6-(benzylamino)purine derivative. The secondary structure is stabilized by  $\text{N}-\text{H}\cdots\text{O}$  hydrogen bonds connecting molecules into centrosymmetric dimers and by weak interatomic contacts of the types  $\text{C}-\text{H}\cdots\text{Cl}$  and  $\text{C}-\text{H}\cdots\text{O}$ , and by  $\pi-\pi$  stacking interactions.


## Comment

In continuation of our systematic crystallographic study of aromatic cytokinins and cyclin-dependent kinase (CDK) inhibitors derived from 6-benzylaminopurine (Trávníček & Zatloukal, 2004; Trávníček & Kryštof, 2004; Trávníček *et al.*, 2006; Trávníček & Rosenker, 2006; Trávníček & Mařarová-Matíková, 2006; Trávníček & Matíková-Mařarová, 2006; Trávníček & Popa, 2007), we now report the structure of the title compound, (I). The synthesis and study of these compounds are motivated by the fact that small changes in the substitution of the 6-benzylaminopurine system, and consequently in the structure, may have a significant impact on their biological activity.



The structure of compound (I) is composed of discrete molecules (Fig. 1). There are three different aromatic rings in the molecule, benzene (A), pyrimidine (B) and imidazole (C). Each ring is essentially planar, the maximum deviations from the mean planes being 0.014 (2) Å for atom C12 (ring A), 0.035 (2) Å for atom C5 (ring B) and 0.007 (2) Å for atom C4 (ring C) (DIAMOND; Brandenburg, 2006). The dihedral angle between ring A and the purine skeleton (consisting of fused rings B and C) is 62.18 (6)°, and that between rings B and C is 4.29 (6)°. However, the latter value differs significantly from those previously reported for C2/N9/phenyl-substituted 6-benzylaminopurines, e.g. *N*-[2-(azepan-1-yl)-9-isopropyl-9*H*-purin-6-yl]-4-methoxybenzylamine [2.99 (4)°;

Received 9 January 2007  
Accepted 11 January 2007




**Figure 1**  
The molecular structure of (I), showing the atomic labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.

Trávníček & Zatloukal, 2004], 6-benzylamino-2-(2-hydroxyethylamino)-9-methylpurine-1,7-dium bis(perchlorate) monohydrate [0.79 (8)<sup>o</sup>; Trávníček & Kryštof, 2004] and 2-chloro-6-[(2,6-dimethoxybenzyl)amino]-9-isopropylpurine 1/8 hydrate [1.77 (6)<sup>o</sup>; Trávníček & Popa, 2007].


Intermolecular N—H···O and O—H···N hydrogen bonds link the molecules into centrosymmetric dimers (Fig. 2, Table 1). There are also some additional intermolecular non-bonding contacts of the types C—H···Cl and C—H···O (Figs. 2 and 3, Table 1), and  $\pi$ – $\pi$  stacking interactions of the type C4···C2 [C4···C2<sup>xiii</sup> = 3.391 (3) Å; symmetry code: (xiii) 1 – x, 1 – y, –1 – z]. The stacking interactions also correspond to a Cg···Cg<sup>xiii</sup> distance of 3.7056 (11) Å, where Cg is the centroid of the ring N1/N3/C2–C6.

## Experimental

The title compound, (I), was prepared as an intermediate during the preparation of a hydroxydimethoxy-Roscovotine derivative by the same procedure as described previously for Roscovitine, *i.e.* 2-[[1-(hydroxymethyl)propyl]amino]-6-benzylamino-9-isopropylpurine



**Figure 2**  
Part of the crystal structure of (I), showing the formation of centrosymmetric dimers connected *via* N6—H6A···O2<sup>i</sup> and O2—H2···N7<sup>i</sup> hydrogen bonds, and the C8—H8A···O1<sup>ii</sup> and C19—H19B···Cl1<sup>iv</sup> non-bonding interactions. These interactions are represented by dashed lines. H atoms not involved in hydrogen bonding have been omitted for clarity. [Symmetry codes: (i) 1 – x, 1 – y, –z; (ii) 1 + x, y, 1 + z; (iv) x, y, z – 1; (v) x, y, 1 + z; (vi) 1 + x, y, 2 + z; (vii) –x, 1 – y, –1 – z; (viii) –x, 1 – y, –2 – z; (ix) 1 – x, 1 – y, –1 – z.]



**Figure 3**  
Part of the crystal structure of (I), showing non-bonding contacts of types C19—H19B···O2<sup>iii</sup> and C19—H19A···O3<sup>iii</sup>, and C4···C2<sup>xiii</sup>  $\pi$ – $\pi$  stacking interactions. These interactions are represented by dashed lines. H atoms not involved in hydrogen bonding have been omitted for clarity. [Symmetry codes: (iii)  $\frac{1}{2} - x, \frac{1}{2} + y, -\frac{1}{2} - z$ ; (x) x, 1 + y, z; (xi) 1 – x, 2 – y, 1 – z; (xii)  $\frac{1}{2} + x, \frac{3}{2} - y, \frac{3}{2} + z$ ; (xiii) 1 – x, 1 – y, 1 – z.]

(Havlíček *et al.*, 1996). The product obtained was recrystallized from hot ethanol and well developed single crystals suitable for X-ray analysis were chosen directly from the mother liquor after several days.

Crystal data

$C_{17}H_{20}ClN_5O_3$   $Z = 4$   
 $M_r = 377.83$   $D_x = 1.455 \text{ Mg m}^{-3}$   
 Monoclinic,  $P2_1/n$  Mo  $K\alpha$  radiation  
 $a = 11.8410(8) \text{ \AA}$   $\mu = 0.25 \text{ mm}^{-1}$   
 $b = 13.5939(9) \text{ \AA}$   $T = 105(2) \text{ K}$   
 $c = 12.1693(8) \text{ \AA}$  Prism, colourless  
 $\beta = 118.318(7)^\circ$   $0.25 \times 0.20 \times 0.20 \text{ mm}$   
 $V = 1724.4(2) \text{ \AA}^3$

Data collection

Oxford Diffraction Xcalibur2 diffractometer 3045 independent reflections  
 $\omega$  scans 2608 reflections with  $I > 2\sigma(I)$   
 Absorption correction: none  $R_{\text{int}} = 0.032$   
 9956 measured reflections  $\theta_{\text{max}} = 25.0^\circ$

Refinement

Refinement on  $F^2$   $w = 1/[\sigma^2(F_o^2) + (0.0402P)^2 + 0.896P]$   
 $R[F^2 > 2\sigma(F^2)] = 0.041$  where  $P = (F_o^2 + 2F_c^2)/3$   
 $wR(F^2) = 0.091$   $(\Delta/\sigma)_{\text{max}} < 0.001$   
 $S = 1.07$   $\Delta\rho_{\text{max}} = 0.25 \text{ e \AA}^{-3}$   
 3045 reflections  $\Delta\rho_{\text{min}} = -0.22 \text{ e \AA}^{-3}$   
 240 parameters  
 H-atom parameters constrained

**Table 1**  
 Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$O2-H2\cdots N7^i$	0.84	1.94	2.717 (2)	153
$N6-H6A\cdots O2^i$	0.88	2.19	3.042 (2)	163
$C8-H8A\cdots O1^{ii}$	0.95	2.50	3.336 (2)	147

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$C19-H19B\cdots O2^{iii}$	0.98	2.65	3.383 (2)	132
$C19-H19A\cdots O3^{iii}$	0.98	2.72	3.101 (2)	104
$C19-H19B\cdots Cl1^{iv}$	0.98	2.90	3.507 (2)	121

Symmetry codes: (i)  $-x + 1, -y + 1, -z$ ; (ii)  $x + 1, y, z + 1$ ; (iii)  $-x + \frac{1}{2}, y + \frac{1}{2}, -z - \frac{1}{2}$ ; (iv)  $x, y, z - 1$ .

All H atoms were located in a difference map and refined using a riding model, with  $C-H = 0.95-0.99 \text{ \AA}$ ,  $N-H = 0.88 \text{ \AA}$  and  $O-H = 0.84 \text{ \AA}$ , and with  $U_{\text{iso}}(H) = 1.2U_{\text{eq}}(C,N)$  or  $1.5U_{\text{eq}}(C_{\text{methyl}},O)$ .

Data collection: *CrysAlis CCD* (Oxford Diffraction, 2002); cell refinement: *CrysAlis RED* (Oxford Diffraction, 2002); data reduction: *CrysAlis RED*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *DIAMOND* (Brandenburg, 2006); software used to prepare material for publication: *SHELXL97* and *DIAMOND*.

The financial support of this work by the Ministry of Education, Youth and Sports of the Czech Republic (grant No. MSM6198959218) is gratefully acknowledged.

References

Brandenburg, K. (2006). *DIAMOND*. Release 3.1d. Crystal Impact GbR, Bonn, Germany.  
 Havlíček, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G. & Strnad, M. (1996). *J. Med. Chem.* **40**, 408–412.  
 Oxford Diffraction (2002). *CrysAlis CCD* and *CrysAlis RED*. Versions 1.69. Oxford Diffraction Ltd., Abingdon, Oxfordshire, England.  
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.  
 Trávníček, Z. & Kryštof, V. (2004). *Acta Cryst.* **E60**, o2324–o2327.  
 Trávníček, Z. & Malarová-Matíková, M. (2006). *Acta Cryst.* **E62**, o4377–o4379.  
 Trávníček, Z., Marek, J. & Popa, I. (2006). *Acta Cryst.* **E62**, o1536–o1538.  
 Trávníček, Z. & Matíková-Malarová, M. (2006). *Acta Cryst.* **E62**, o5097–o5099.  
 Trávníček, Z. & Popa, I. (2007). *Acta Cryst.* **E63**, o629–o631.  
 Trávníček, Z. & Rosenker, C. J. (2006). *Acta Cryst.* **E62**, o3393–o3395.  
 Trávníček, Z. & Zatloukal, M. (2004). *Acta Cryst.* **E60**, o924–o926.